MAIA Biotechnology presents next-generation telomere-targeting cancer drug candidates at IRT 2026 - MAIA News | RalliesMAIA Biotechnology presents next-generation telomere-targeting cancer drug candidates at IRT 2026
M
MAIA• Preclinical results presented in Barcelona
- Maia Biotechnology disclosed preclinical results for next-generation telomere-targeting cancer candidates at IRT 2026 in Barcelona.
- Data presented point to stronger anticancer activity for divalent prodrug designs versus ateganosine alone, supporting pipeline expansion efforts.
- Work highlighted a strategy to combine telomere damage with a complementary DNA-targeting agent to lift efficacy across tumor types.
•
